Type 2 diabetes is a chronic disease characterized by progressive worsening of glycaemic
control as indicated by the United Kingdom Prospective Diabetes Study (UKPDS). The …

Despite intervention with effective oral glucose‐lowering agents, most patients with type 2
diabetes will experience a gradual loss of glycaemic control. Irrespective of underlying …

Insulin resistance is a common pathogenetic feature of type 2 diabetes. However,
hyperglycemia would not develop if a concomitant defect in insulin secretion were not …

Beta cell deficiency underlies both type 1 and type 2 diabetes, and restoration or
replacement of beta cell function is therefore the logical long-term solution to therapy. This …

Different in vivo tests explore different aspects of β-cell function. Because intercorrelation of
insulin secretion indices is modest, no single in vivo test allows β-cell function to be …

The healthy β‐cell has an enormous capacity to adapt to conditions of higher insulin
demand (eg in obesity, pregnancy, cortisol excess) to maintain normoglycaemia with an …

Discusses prospects for the reversal or prevention of Beta-cell deterioration, which is a
major factor influencing the progression from normal glucose tolerance to type 2 diabetes …

OBJECTIVE—β-Cell regeneration is a fundamental but elusive goal for type 1 diabetes
research. Our objective is to review newer human and animal studies of β-cell destruction …

The goal for the treatment of patients with diabetes has today shifted from merely reducing
glucose concentrations to preventing the natural decline in β-cell function and delay the …

Type 2 diabetes is the most common form of diabetes in humans and results from a
combination of genetic and acquired factors that impair-cell function and tissue insulin …